Securities: Litigation: Mainly Plaintiff (Nationwide)
What the team is known for: Dedicated team of plaintiff-side attorneys, considered a go-to for international and domestic clients bringing securities claims in the USA and other jurisdictions. Noted in particular for unparalleled expertise in shareholder litigation resulting from M&A. Continues to be prominent in class action, opt-out and institutional investor litigation, and has an impressive track record of negotiating record-breaking settlement deals.
Strengths: “They are held in high esteem by judges and have a well-earned reputation,” notes one impressed source.
Work highlights: Represented a group of institutional investors to bring a securities fraud action against the Royal Bank of Scotland before the High Court in London under UK law.
Served as class counsel to a group of institutional investors in a securities class action case against Pfizer.
Chancery: Mainly Plaintiff (Delaware)
What the team is known for: A highly regarded plaintiffs’ firm that retains its leading reputation in the chancery space. Has an exemplary track record in recovering impressive sums on behalf of investors in M&A litigation and shareholder disputes. Also known for its expertise in corporate governance matters.
Strengths: One interviewee says: “The results they get are impressive, they’re second to none.”
Stuart Grant offers impressive experience litigating matters including proxy contests, appraisal remedies and fiduciary responsibility breaches before the Delaware Chancery Court. Sources describe him as “a phenomenal attorney and advocate” and add: “He knows how to get results and drive cases from the plaintiff side.”
Litigation: Securities Mainly Plaintiff (New York)
What the team is known for: Renowned plaintiffs’ firm that is highly recommended for its expertise in litigating complex securities disputes, including deep experience practicing before the Delaware Court of Chancery. Notable track record in securing high-profile results for clients in class action, opt-out and individual claims. Counts leading multinational institutional investors among its client roster and is frequently retained in litigation involving multiple jurisdictions.
Work highlights: Worked with an institutional investor to negotiate a $486 million settlement with Pfizer, following a long-running dispute alleging the company misrepresented the cardiovascular safety of its arthritis drugs Celebrex and Bextra.
Advised a number of institutional investors to bring claims against the Royal Bank of Scotland over the bank’s 2008 rights offering, alleging the associated prospectus contained numerous material misrepresentations and omissions concerning its subprime-related credit market exposure.
Managing director Jay Eisenhofer has an illustrious standing in the market for his abilities in plaintiff-side securities claims. He boasts an impressive track record of achieving notable settlements for a number of institutional investors.
From Chambers USA 2018